AI facts
As at Fri 9 Oct 2026Quabbin Clinical Research holds an Enterprise order form signed 23 Mar 2026 at £119k a year after a 5.0% first-term discount, running 7 Apr 2026 to 6 Apr 2027. In Sep 2026 there were 148 active users against 150 licensed users and 16 connectors configured. Renewal on 7 Apr 2027 is priced at £125k, and INV-233-0004 for £30k is open, due 6 Nov 2026. A ticket opened 8 Oct 2026 reports a study source that has stopped loading new records.
Profile
Updated 9 Oct 26- IndustryContract researchSource: CRM company record
- Websitequabbin.exampleSource: CRM company record
- CountryUnited StatesSource: CRM company record · CRM code US · Region US
- HQ cityBostonSource: CRM company record
- Size1,600 employeesSource: CRM company record
- CRM ownerJordan PikeSource: CRM company record · Account Executive, US · CSM Hollie Grieve
- Customer since7 Apr 2026Source: first executed order form ctr_233_01, signed 23 Mar 2026 · Enterprise tier · In the CRM since 23 Dec 2025
- TypeCustomerSource: contracts and invoices (signals) · CRM stage customer
- StateHealthySource: AI assessment · As at Fri 9 Oct 2026 · written 21 Oct 2026
AI opinion
As at Fri 9 Oct 2026Healthy, because active users and questions keep rising, questions are spread widely and the three paid invoices were settled within terms. Meredith Sullivan has not committed renewal budget, and the stopped study source needs a cause and a date. With 148 of 150 seats active, additional users are an opening.
Key facts
Updated 9 Oct 26- Contracted ARR£118,750differsSource: executed order form ctr_233_01, 7 Apr 2026 to 6 Apr 2027 · CRM £125,000 · Invoiced run rate £118,752 · As of 9 Oct 2026 · The sources disagree
- Next renewal7 Apr 2027Basis: order form ctr_233_01 ends 6 Apr 2027 · In 180 days · Renewal price £125,000 (+5.3%) · list price of the tier on the renewal date (price book); v1 prices and first-term discounts end at renewal
- Term7 Apr 2026 to 6 Apr 2027Source: order form ctr_233_01 (new), signed 23 Mar 2026 · Billed quarterly · 150 seats, 20 connectors
- TierEnterpriseSource: the current order form
- Last contact7 Oct 2026Email: Invoice INV-233-0004 · 2 days before 9 Oct 2026
- Tenantus-east-1Source: product analytics, reporting since Apr 2026 · 16 connectors configured
- Licensed seats150148 active users in Sep 2026 · Order form ctr_233_01: 150 seats
Next step
As at Fri 9 Oct 2026- What
- Hollie Grieve gives Meredith Sullivan a confirmed cause, a fix date and any freshness credit owed for the study source that stopped loading on 8 Oct 2026. delivery
- Who
Hollie Grieve
- When
- This week by 9 Oct 2026
- Why
- Hollie Grieve should give Meredith Sullivan a cause and a dated fix for the study source that stopped loading on 8 Oct 2026. Enterprise freshness credits apply, and her renewal budget is still uncommitted.
The story
As at Fri 9 Oct 2026Healthy: Enterprise at £119k a year to 6 Apr 2027, with active users up from 79 to 148 against 150 seats. A study source stopped loading on 8 Oct 2026 and renewal budget is uncommitted. Hollie Grieve owes Meredith Sullivan a cause and a fix date.
Healthy: Quabbin Clinical Research holds an executed Enterprise order form at £119k a year from 7 Apr 2026 to 6 Apr 2027. Renewal on 7 Apr 2027 is priced at £125k, a 5.3% rise.
Active users rose from 79 in May 2026 to 148 in Sep 2026, against 150 licensed seats, and questions rose from 2392 to 8964. Use is spread: Kristen Zimmerman asks 8% over 90 days, and the champion, Meredith Sullivan, calls the value story easy to tell.
A study source stopped loading in a ticket opened 8 Oct 2026, and the customer has been given no cause or fix date. The main risk is renewal budget: Meredith committed nothing at the 16 Sep 2026 QBR.
Hollie Grieve owns the next step: give Meredith a confirmed cause, a fix date and any freshness credit owed, by 9 Oct 2026. Jordan Pike then prepares an additional users offer.
ARR journey
Updated 9 Oct 26One point per month; the dot and figure at the right end are the latest value. Dashed upright lines mark dated events. Latest (Sep 26): Contracted ARR £119k; Invoiced ARR £119k. Basis: accounting system, facts.arr_monthly:org_233.
Show the figures as a table
| Month | Contracted ARR | Invoiced ARR |
|---|---|---|
| Apr 26 | £118,750 | £118,752 |
| May 26 | £118,750 | £118,752 |
| Jun 26 | £118,750 | £118,752 |
| Jul 26 | £118,750 | £118,752 |
| Aug 26 | £118,750 | £118,752 |
| Sep 26 | £118,750 | £118,752 |
Finance read
As at Fri 9 Oct 2026ARR £119k, one invoice open
Contracted ARR is £119k on the Enterprise order form, in place since Apr 2026. INV-233-0004 for £30k is open and due 6 Nov 2026. Renewal on 7 Apr 2027 is priced at £125k.
- INV-233-0004 for £30k is open, due 6 Nov 2026, not yet past due
- Over-billing of £3 owed back across three invoices
- Renewal on 7 Apr 2027 priced at £125k
The analysis
Recurring revenue: The executed Enterprise order form gives contracted ARR of £119k, billed quarterly, with a 5.0% discount on a £125k list price. ARR moved once, when it began in Apr 2026.
Next commitment: Renewal falls on 7 Apr 2027, priced at £125k against £119k today, a change of +£6,250 (5.3%) as the first-term discount ends.
Billing: INV-233-0001, INV-233-0002 and INV-233-0003 were paid within terms. INV-233-0004 for £29,688 is open, due 6 Nov 2026 and not yet past due. Invoices run at £29,688 a quarter against £29,687 in the order form, £3 owed back.
Reconciliation: CRM ARR is £125k and the invoiced run rate is £118,752. The executed order form at £118,750 is the truth.
Deals: the one new Enterprise deal is closed won, owned by Jordan Pike, who is active in HR.
Made from 1 deal · 3 fact tables · 4 invoices
History by quarter
As at Fri 9 Oct 2026Each earlier quarter in one AI digest of its calls, email threads, tickets and news, newest first; from 1 Jul 2026 the assessment reads every one of them itself.
- Q2 2026
Q2 2026: Enterprise onboarding, recovery
Enterprise onboarding began 15 Apr 2026. A stalled study management connector, a sponsor access slip and thin use against 150 seats caused concern in May. By mid-June it had recovered, with positive training, but use stayed low.
The analysis
Kickoff: On 15 Apr 2026 Hollie Grieve confirmed the order form was signed on 7 Apr 2026, with £119k matching invoices. Meredith Sullivan called sponsor separation non-negotiable and Rachel Feldman named access design as her main worry.
Connectors: CRM loading began on 21 Apr 2026. On 29 Apr 2026 the study management system had no committed timing and no known export owner.
Problems: On 7 May 2026 a test user saw a sponsor she should not cover, and study data was incomplete. Meredith asked whether Quabbin will get what it bought.
Stall: On 13 May 2026 the study connector stopped after a credential change, and only a handful of users had logged in. On 20 May 2026 Rachel said further rollout depended on closing two priority tickets.
Adoption: On 28 May 2026 credit notes did not match finance totals. On 3 Jun 2026 about fifteen people used B-Viz, and Rachel was the only admin.
Support: Dashboard sharing steps were wrong on 5 May 2026. A duplicate invoice line, reproduced on 1 Jun 2026, made finance distrust the page.
Recovery: On 11 Jun 2026 the connector had loaded cleanly, a second admin was in place and about seventeen users were active. Training on 15 Jun 2026 and 19 Jun 2026 went well.
Open at the end: Provisioning scope was unconfirmed, and Meredith said finance wants to see usage before budget or expansion. The CFO and security lead invitations had no reply.
Quabbin Clinical Research / BG-Demo – KickoffQuabbin Clinical Research / BG-Demo – OnboardingQuabbin Clinical Research / BG-Demo – OnboardingOnboarding session follow-upQuabbin Clinical Research / BG-Demo – OnboardingQuabbin Clinical Research / BG-Demo – OnboardingQuabbin Clinical Research / BG-Demo – TrainingMade from 10 calls · 11 email threads · 5 tickets
- Q1 2026
Q1 2026: Enterprise deal, order form unsigned
Prospect moved from discovery to an Enterprise order form for £149k total. The CFO pressed for the annual cost split from implementation. Signature waited on his legal team, and an implementation invoice went out on 24 Mar 2026.
The analysis
Discovery: On 7 Jan 2026 Meredith Sullivan agreed to a discovery call. On 13 Jan 2026 she asked for one view per sponsor with strict separation, and Gregory Tanaka asked for the annual cost.
Demo: On 29 Jan 2026 the demo on the customer's sample extract went well. Open worries were sponsor separation, the quality of study and sponsor matching, and the clunky study system export.
Proposal: On 17 Feb 2026 the Enterprise proposal was walked through. Gregory would not call the 23 Mar 2026 close firm, and on 19 Feb 2026 he asked in writing for the annual cost and implementation fee shown separately.
Negotiation: On 5 Mar 2026 Gregory said he signs only after information security and sourcing finish, with no completion date. Owen Tallis said any discount applies to the first term only and ends at the first renewal.
Order form: On 9 Mar 2026 Gregory again asked for the annual figure. On 19 Mar 2026 he accepted that the lines were separate but would not sign until legal confirmed.
Billing: On 24 Mar 2026 an invoice for £30k net, due 23 Apr 2026, was sent with a request for a PO number.
Open at the end: No executed order form is shown. The invoice has no customer reply, and the security and sourcing reviews have no completion date. The webinar invitations to the CFO and the security director drew no replies.
Quabbin Clinical Research / BG-Demo – DiscoveryQuabbin Clinical Research / BG-Demo – DemoQuabbin Clinical Research / BG-Demo – ProposalQuabbin Clinical Research / BG-Demo – NegotiationFollow-up on the proposalOrder form for signatureInvoice INV-233-0001 for Quabbin Clinical ResearchMade from 4 calls · 8 email threads
- Q4 2024
Q4 2024: one unanswered roundtable invite
One read in the period: on 17 Nov 2024 Sofia Marchetti invited Derek Lindqvist, Controller, to a London roundtable on 26 Nov 2024. The thread shows no reply, so his interest is not shown.
The analysis
Period: this digest rests on one read, an email thread dated 17 Nov 2024. There were no calls, tickets or news items in the quarter.
Invitation: Sofia Marchetti invited Derek Lindqvist, Controller, to an in-person revenue leaders roundtable in London on 26 Nov 2024. She described it as informal and free of charge, about how finance and sponsor-facing teams share one picture of each relationship, with no sales presentation.
Customer view: the thread holds no response from Derek, so the evidence does not show his interest or whether he attended.
Open at the end: Sofia was waiting for a reply to confirm details, or for topics Derek would find useful if he could not attend. The read sees a possible opening with a finance contact on joining customer, contract and invoice data in B-Viz. It also notes the risk that finance engagement with BG-Demo stays unconfirmed.
Made from 1 email thread
Platform usage
Updated 9 Oct 26Questions asked are read on the right axis, on their own scale, and users on the left: questions run to thousands a month where users run to hundreds. The dotted line is the allowance. Latest (Sep 26): Active users 148; Licensed seats 150; Questions asked 8,964. Basis: product usage, facts.usage_monthly:org_233, signals:org_233.
Show the figures as a table
| Month | Active users | Licensed seats | Questions asked |
|---|---|---|---|
| Apr 26 | 44 | 150 | 1,024 |
| May 26 | 79 | 150 | 2,392 |
| Jun 26 | 106 | 150 | 4,834 |
| Jul 26 | 125 | 150 | 7,443 |
| Aug 26 | 144 | 150 | 4,801 |
| Sep 26 | 148 | 150 | 8,964 |
Data volume is read on the right axis, in GB, and connectors and admins on the left, as counts: one scale would flatten the counts. The dotted line is the allowance. Latest (Sep 26): Connectors configured 16; Active admins 3; Data volume 119 GB. Basis: product usage, facts.usage_monthly:org_233, signals:org_233.
Show the figures as a table
| Month | Connectors configured | Active admins | Data volume |
|---|---|---|---|
| Apr 26 | 0 | 3 | 0.00 GB |
| May 26 | 7 | 3 | 48.08 GB |
| Jun 26 | 11 | 3 | 77.02 GB |
| Jul 26 | 12 | 3 | 85.66 GB |
| Aug 26 | 15 | 3 | 109.14 GB |
| Sep 26 | 16 | 3 | 118.53 GB |
Usage read
As at Fri 9 Oct 2026Usage rising, seats nearly full
Usage is rising: questions 6,002 to 8,298 (+38%) over the last four weeks against the four before. 148 of 150 seats were active in September 2026. Questions are spread widely, with no one above 8%.
- Questions 6,002 to 8,298 (+38%) over the last four weeks
- 148 of 150 seats active (99%)
- 16 of 20 contracted connectors configured
- No person above 8% of questions
The analysis
Recent weeks: After a lower stretch in the weeks ending 7 Aug 2026 to 28 Aug 2026, usage climbed from the week ending 4 Sep 2026. The last four weeks against the four before show questions 6,002 to 8,298 (+38%) and average daily active users 36.2 to 48.0 (+33%).
Trend: Active users grew from 44 in April 2026 to 148 in September 2026 (+236%), and September questions of 8,964 are the peak. The busiest week was the week ending 2 Oct 2026 with 2,279 questions.
Who uses it: Meredith Sullivan, Gregory Tanaka and Rachel Feldman are the active admins. Over 90 days Kristen Zimmerman asks 1,942 questions (8%) and Gregory Tanaka 1,629 (7%), so there is no concentration.
Against the order form: the Enterprise order form gives 150 seats and 20 connectors. 148 users were active in September 2026 (99% of seats) and 16 connectors are configured.
Made from 2 fact tables
Documents
Updated 9 Oct 26- commercial
- delivery
- presales
Folders and documents as a list
- Contracts (4)
- Draft Enterprise master services agreement draft · contract · 5 Mar 2026
- Signed Enterprise master agreement executed · contract · 23 Mar 2026
- Signed data processing agreement executed · dpa · 23 Mar 2026
- Signed Enterprise order form executed · order form · 23 Mar 2026
- Onboarding (1)
- Enterprise onboarding plan issued · onboarding plan · 13 Apr 2026
- Proposals (2)
- Draft Enterprise proposal draft · proposal · 11 Feb 2026
- Enterprise B-Viz proposal issued · proposal · 16 Feb 2026
- QBRs (1)
- Quarterly review ahead of renewal issued · qbr deck · 15 Sep 2026
- Security (1)
- Enterprise security questionnaire answers issued · security questionnaire · 1 Feb 2026
Open deals
Open tickets
- 8 Oct 2026 233-0010 connector_sync
- 7 Oct 2026 233-0009 access_permissions
Activity
- 8 Oct 2026ticketStudy source has stopped loading into B-Viz
- 7 Oct 2026ticketNew finance users cannot see sponsor invoices
- 7 Oct 2026email threadInvoice INV-233-0004
- 7 Oct 2026invoiceINV-233-0004
- 29 Sep 2026ticketSponsor pages slow to load
- 16 Sep 2026callQuabbin Clinical Research / BG-Demo – QBR
+1
- 15 Sep 2026documentQuabbin Clinical Research - QBR
- 11 Sep 2026ticketInvoice needs reissuing against our purchase order
- 11 Sep 2026email threadSetting up your quarterly business review
- 17 Aug 2026callQuabbin Clinical Research / BG-Demo – Check In
- 7 Aug 2026email threadCatching up: check-in call
- 16 Jul 2026eventBG-Demo webinar
+53
- 14 Jul 2026ticketStudy records appearing twice
- 7 Jul 2026email threadInvoice INV-233-0003 for Quabbin Clinical Research
- 7 Jul 2026invoiceINV-233-0003
- 1 Jul 2026email threadInvitation: BG-Demo webinar
- 19 Jun 2026callQuabbin Clinical Research / BG-Demo – Training
- 15 Jun 2026callQuabbin Clinical Research / BG-Demo – Training
- 11 Jun 2026eventBG-Demo Customer Day London
+116
- 11 Jun 2026callQuabbin Clinical Research / BG-Demo – Onboarding
- 10 Jun 2026email threadTraining session for the sponsor relations team
- 8 Jun 2026email threadOnboarding session: finding a time
- 6 Jun 2026email threadInvitation: BG-Demo Customer Day London
- 3 Jun 2026callQuabbin Clinical Research / BG-Demo – Onboarding
- 1 Jun 2026ticketDuplicate invoice line on a sponsor page
- 28 May 2026callQuabbin Clinical Research / BG-Demo – Onboarding
- 21 May 2026eventBG-Demo webinar
+44
- 20 May 2026email threadOnboarding session follow-up
- 18 May 2026email threadInvitation to BG-Demo Customer Day London
- 13 May 2026callQuabbin Clinical Research / BG-Demo – Onboarding
- 7 May 2026ticketHelp getting sponsor data loaded during onboarding
- 7 May 2026callQuabbin Clinical Research / BG-Demo – Onboarding
- 5 May 2026ticketURGENT: access steps not working, need help today
- 3 May 2026email threadInvitation: BG-Demo webinar on Thursday 21 May 2026
- 29 Apr 2026callQuabbin Clinical Research / BG-Demo – Onboarding
- 28 Apr 2026email threadOnboarding sessions: finding a time
- 22 Apr 2026ticketHow to restrict a dashboard to a group of users
- 21 Apr 2026callQuabbin Clinical Research / BG-Demo – Onboarding
- 16 Apr 2026email threadKickoff follow-up and next steps
+1
- 15 Apr 2026callQuabbin Clinical Research / BG-Demo – Kickoff
+1
- 14 Apr 2026email threadOnboarding session: admin setup
- 13 Apr 2026documentQuabbin Clinical Research - Onboarding Plan
- 9 Apr 2026email threadKickoff call: finding a time
- 7 Apr 2026ticketStudy issues not showing in the sponsor portfolio view
- 7 Apr 2026email threadInvoice INV-233-0002 for Quabbin Clinical Research
- 7 Apr 2026invoiceINV-233-0002
- 24 Mar 2026email threadInvoice INV-233-0001 for Quabbin Clinical Research
- 24 Mar 2026invoiceINV-233-0001
- 23 Mar 2026documentQuabbin Clinical Research - Order Form (signed)
- 23 Mar 2026documentQuabbin Clinical Research - Data Processing Agreement (signed)
- 23 Mar 2026documentQuabbin Clinical Research - Master Services Agreement (signed)
- 19 Mar 2026email threadOrder form for signature
- 19 Mar 2026eventBG-Demo webinar
+41
- 11 Mar 2026email threadInvitation: BG-Demo webinar on 19 Mar 2026
- 9 Mar 2026email threadQuabbin and BG-Demo: where we are on the Enterprise terms
- 5 Mar 2026documentQuabbin Clinical Research - Master Services Agreement v2
- 5 Mar 2026callQuabbin Clinical Research / BG-Demo – Negotiation
- 27 Feb 2026email threadScheduling the negotiation call
- 19 Feb 2026email threadFollow-up on the proposal
- 19 Feb 2026eventBG-Demo webinar
+40
- 17 Feb 2026callQuabbin Clinical Research / BG-Demo – Proposal
- 16 Feb 2026documentQuabbin Clinical Research - Proposal
- 11 Feb 2026documentQuabbin Clinical Research - Proposal v1
- 1 Feb 2026documentQuabbin Clinical Research - Security Questionnaire
- 29 Jan 2026email threadInvitation: BG-Demo webinar on Thursday 19 February 2026
- 29 Jan 2026callQuabbin Clinical Research / BG-Demo – Demo
+1
- 13 Jan 2026callQuabbin Clinical Research / BG-Demo – Discovery
- 7 Jan 2026email threadSetting up a discovery call
- 23 Dec 2025dealQuabbin Clinical Research – New
- 26 Nov 2024eventRevenue leaders roundtable
+40
- 17 Nov 2024email threadInvitation: revenue leaders roundtable in London
Contacts
Evidence trail
Updated 9 Oct 26Quabbin Clinical Research's pages are written from 3 organisation-level AI texts (assessment / next steps), 3 period digests and 1 narrative-level AI text, which in turn draw on 60 AI summaries of 65 raw things (calls, tickets, emails, news), 1 usage read, 1 finance read, 13 people (13 with an AI write-up) and 5 staff (0 with an AI write-up), shown on 14 pages.
The trail as a list (block, record, entity, raw row)
- Activity page block
- Quabbin Clinical Research / BG-Demo – Discovery entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- call_recorder/calls.csv call_233_001 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research / BG-Demo – Demo entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- call_recorder/calls.csv call_233_002 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research / BG-Demo – Proposal entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- call_recorder/calls.csv call_233_003 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research / BG-Demo – Negotiation entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- call_recorder/calls.csv call_233_004 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research / BG-Demo – Kickoff entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- call_recorder/calls.csv call_233_005 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research / BG-Demo – Onboarding entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- call_recorder/calls.csv call_233_006 raw row
- Quabbin Clinical Research entity
- +65 more
- Quabbin Clinical Research / BG-Demo – Discovery entity
- AI opinion page block
- Quabbin Clinical Research healthy AI record
- Quabbin: Enterprise paper executed 23 Mar 2026 AI record
- Quabbin Clinical Research - Security Questionnaire entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- document_store/files.csv doc_233_001 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research - Proposal v1 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- document_store/files.csv doc_233_002 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research - Proposal entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- document_store/files.csv doc_233_003 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research - Master Services Agreement v2 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- document_store/files.csv doc_233_004 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research - Master Services Agreement (signed) entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- document_store/files.csv doc_233_005 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research - Data Processing Agreement (signed) entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- document_store/files.csv doc_233_006 raw row
- Quabbin Clinical Research entity
- +13 more
- Quabbin Clinical Research - Security Questionnaire entity
- ARR £118,750, one invoice open AI record
- Quabbin Clinical Research – New entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- contracts/order_form_lines.csv ctr_233_01:1 raw row
- contracts/order_form_lines.csv ctr_233_01:2 raw row
- contracts/order_forms.csv ctr_233_01 raw row
- crm/deal_line_items.csv deal_233_01:1 raw row
- crm/deal_line_items.csv deal_233_01:2 raw row
- +7 more
- Quabbin Clinical Research entity
- facts.arr_monthly:org_233 facts table
- Quabbin Clinical Research – New entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- contracts/order_form_lines.csv ctr_233_01:1 raw row
- contracts/order_form_lines.csv ctr_233_01:2 raw row
- contracts/order_forms.csv ctr_233_01 raw row
- crm/deal_line_items.csv deal_233_01:1 raw row
- crm/deal_line_items.csv deal_233_01:2 raw row
- +7 more
- Quabbin Clinical Research entity
- INV-233-0001 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_001:1 raw row
- accounting/invoices.csv inv_233_001 raw row
- accounting/payments.csv pay_233_001 raw row
- Quabbin Clinical Research entity
- INV-233-0002 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_002:1 raw row
- accounting/invoices.csv inv_233_002 raw row
- accounting/payments.csv pay_233_002 raw row
- Quabbin Clinical Research entity
- INV-233-0003 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_003:1 raw row
- accounting/invoices.csv inv_233_003 raw row
- accounting/payments.csv pay_233_003 raw row
- Quabbin Clinical Research entity
- INV-233-0004 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_004:1 raw row
- accounting/invoices.csv inv_233_004 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research – New entity
- facts.debtors:org_233 facts table
- INV-233-0004 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_004:1 raw row
- accounting/invoices.csv inv_233_004 raw row
- Quabbin Clinical Research entity
- INV-233-0004 entity
- facts.reconciliation_t0:org_233 facts table
- Quabbin Clinical Research – New entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- contracts/order_form_lines.csv ctr_233_01:1 raw row
- contracts/order_form_lines.csv ctr_233_01:2 raw row
- contracts/order_forms.csv ctr_233_01 raw row
- crm/deal_line_items.csv deal_233_01:1 raw row
- crm/deal_line_items.csv deal_233_01:2 raw row
- +7 more
- Quabbin Clinical Research entity
- INV-233-0001 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_001:1 raw row
- accounting/invoices.csv inv_233_001 raw row
- accounting/payments.csv pay_233_001 raw row
- Quabbin Clinical Research entity
- INV-233-0002 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_002:1 raw row
- accounting/invoices.csv inv_233_002 raw row
- accounting/payments.csv pay_233_002 raw row
- Quabbin Clinical Research entity
- INV-233-0003 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_003:1 raw row
- accounting/invoices.csv inv_233_003 raw row
- accounting/payments.csv pay_233_003 raw row
- Quabbin Clinical Research entity
- INV-233-0004 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_004:1 raw row
- accounting/invoices.csv inv_233_004 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- Quabbin Clinical Research – New entity
- INV-233-0001 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_001:1 raw row
- accounting/invoices.csv inv_233_001 raw row
- accounting/payments.csv pay_233_001 raw row
- Quabbin Clinical Research entity
- INV-233-0002 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_002:1 raw row
- accounting/invoices.csv inv_233_002 raw row
- accounting/payments.csv pay_233_002 raw row
- Quabbin Clinical Research entity
- +3 more
- Quabbin Clinical Research – New entity
- Check-in: adoption growing, no issues AI record
- Quabbin Clinical Research / BG-Demo – Check In entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- call_recorder/calls.csv call_233_015 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- Quabbin Clinical Research / BG-Demo – Check In entity
- QBR: healthy usage, Sandbox and renewal AI record
- Quabbin Clinical Research / BG-Demo – QBR entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- call_recorder/calls.csv call_233_016 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- Quabbin Clinical Research / BG-Demo – QBR entity
- Customer webinar invitation AI record
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- Invitation: BG-Demo webinar entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- mailbox/messages.csv thr_233_0021:1 raw row
- mailbox/threads.csv thr_233_0021 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research entity
- Invoice INV-233-0003 issued AI record
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- Invoice INV-233-0003 for Quabbin Clinical Research entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- mailbox/messages.csv thr_233_0022:1 raw row
- mailbox/threads.csv thr_233_0022 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research entity
- +27 more
- Quabbin: Enterprise paper executed 23 Mar 2026 AI record
- Quabbin Clinical Research healthy AI record
- ARR journey page block
- facts.arr_monthly:org_233 facts table
- Quabbin Clinical Research – New entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- contracts/order_form_lines.csv ctr_233_01:1 raw row
- contracts/order_form_lines.csv ctr_233_01:2 raw row
- contracts/order_forms.csv ctr_233_01 raw row
- crm/deal_line_items.csv deal_233_01:1 raw row
- crm/deal_line_items.csv deal_233_01:2 raw row
- +7 more
- Quabbin Clinical Research entity
- INV-233-0001 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_001:1 raw row
- accounting/invoices.csv inv_233_001 raw row
- accounting/payments.csv pay_233_001 raw row
- Quabbin Clinical Research entity
- INV-233-0002 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_002:1 raw row
- accounting/invoices.csv inv_233_002 raw row
- accounting/payments.csv pay_233_002 raw row
- Quabbin Clinical Research entity
- INV-233-0003 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_003:1 raw row
- accounting/invoices.csv inv_233_003 raw row
- accounting/payments.csv pay_233_003 raw row
- Quabbin Clinical Research entity
- INV-233-0004 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- accounting/invoice_lines.csv inv_233_004:1 raw row
- accounting/invoices.csv inv_233_004 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research – New entity
- facts.arr_monthly:org_233 facts table
- AI facts page block
- Quabbin Clinical Research healthy AI record
- Quabbin: Enterprise paper executed 23 Mar 2026 AI record
- Quabbin Clinical Research - Security Questionnaire entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- document_store/files.csv doc_233_001 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research - Proposal v1 entity
- Quabbin Clinical Research entity
- accounting/customers.csv org_233 raw row
- crm/companies.csv org_233 raw row
- product_analytics/tenants.csv org_233 raw row
- document_store/files.csv doc_233_002 raw row
- Quabbin Clinical Research entity
- Quabbin Clinical Research - Proposal entity
- +13 more
- Quabbin Clinical Research - Security Questionnaire entity
- +27 more
- Quabbin: Enterprise paper executed 23 Mar 2026 AI record
- Quabbin Clinical Research healthy AI record
- Contacts page block
- +7 more
- Open deals (computed from the records; nothing to show yet) page block
- Documents page block
- +3 more
- Finance read page block
- hero page block
- History by quarter page block
- Key facts page block
- Evidence trail page block
- The story page block
- Next step page block
- Open tickets page block
- Profile page block
- Sources page block
- Platform usage page block
- Usage read page block